During the past decade, CAP Casanova conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "CAP Casanova" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "CAP Casanova" are "Diabetes Mellitus, Type 2" (1 trials) and "Pulmonary Disease, Chronic Obstructive" (1 trials). Many other conditions were trialed in "CAP Casanova" in a lesser frequency.

Most popular intervention types in "CAP Casanova" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Inhaled corticosteroid" (1 trials), "glimepiride" (1 trials), "glimepiride placebo" (1 trials), "linagliptin" (1 trials) and "linagliptin placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "CAP Casanova" are 2 trials for "All" genders.

Currently, there are NaN active trials in "CAP Casanova". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in CAP Casanova, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CAP Casanova, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".